Several lines of evidence suggest that TAK1 possesses the ability to activate the downstream JNK/AP-1 and IKK/NK-κB pathways, leading to RCC progression (Hui et al., 2018; Aashaq et al., 2019). Here, FOS is linked to renal cell carcinoma.